(Q46059122)

19 December 2017

title

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status (English)

1 reference

19 December 2017

glucocorticoid-induced osteoporosis

main subject

osteoporosis

0 references

1 reference

B L Langdahl

1

1 reference

19 December 2017

F Marin

2

1 reference

19 December 2017

E Shane

3

1 reference

19 December 2017

H Dobnig

4

1 reference

19 December 2017

J R Zanchetta

5

1 reference

19 December 2017

M Maricic

6

1 reference

19 December 2017

K Krohn

7

1 reference

19 December 2017

K See

8

1 reference

19 December 2017

M R Warner

9

1 reference

19 December 2017

language of work or name

English

0 references

publication date

7 April 2009

1 reference

19 December 2017

Osteoporosis International

published in

1 reference

19 December 2017

volume

20

1 reference

19 December 2017

issue

12

1 reference

19 December 2017

page(s)

2095-2104

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s00198-009-0917-y

exact match

0 references

cites work

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

1 reference

12 December 2020

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells

1 reference

12 December 2020

Use of oral corticosteroids and risk of fractures.

1 reference

12 December 2020

Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

12 December 2020

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data

1 reference

12 December 2020

Mechanisms of glucocorticoid-induced myopathy

1 reference

12 December 2020

Corticosteroid induced osteoporosis. Guidelines for treatment

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

1 reference

12 December 2020

High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease

1 reference

12 December 2020

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.

1 reference

12 December 2020

Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology

1 reference

12 December 2020

A method to assess the proportion of treatment effect explained by a surrogate endpoint

1 reference

12 December 2020

Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence

1 reference

12 December 2020

1 reference

12 December 2020

Glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

12 December 2020

Molecular mechanisms of action of bisphosphonates.

1 reference

12 December 2020

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

1 reference

12 December 2020

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

12 December 2020

A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk

1 reference

12 December 2020

Mechanisms of anabolic therapies for osteoporosis

1 reference

12 December 2020

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

1 reference

12 December 2020

Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.

1 reference

12 December 2020

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

The epidemiology of glucocorticoid-associated adverse events

1 reference

12 December 2020

Anabolic therapy in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

12 December 2020

Oral glucocorticoid use is associated with an increased risk of fracture

1 reference

12 December 2020

Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone

1 reference

12 December 2020

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

1 reference

12 December 2020

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

1 reference

12 December 2020

10.1007/S00198-009-0917-Y

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017